Plasmafabriek Sanquin


For the prevention of tetanus.


Production of TetaQuin has stopped.

The distribution of the replacement product Tetanus Gamma with ZI number 16984390 will be provided by Orly Pharma as of July 1st, 2021.

For questions and orders, please contact: [email protected], tel: 077 351 92 75.

Product information

Sanquin Plasma Products (SPP) has decided to stop producing hyperimmune products, also called Quins, including TetaQuin.

In recent years, SPP has facilitated the supply of a replacement product, not registered in the Netherlands, Tetanus Gamma (ZI nummer 16984390), using the so-called ‘Staatscourant’ route for the last 2 years. This route is no longer possible as it is no longer a temporary shortage but a permanent shortage. The consequence of this is that as of 1 January 2021 a doctor's declaration must be sent for Tetanus Gamma together with the order. You can find this here (in Dutch). 

As there is no replacement product in the Netherlands and it concerns a serious indication, Sanquin has ensured that, with the permission of the Inspectorate for Health and Youth Care (IGJ), an equivalent alternative is available. This is Tetanus Gamma 250 IU/ml from Kedrion in a pre-filled syringe of 1 ml. 
The Tetanus Gamma product is an equivalent product covering the same range of symptoms and has the same dosage advice as TetaQuin. An English language SPC has been added.

SPC: product characteristics (Tetanus Gamma)

  • When is TetaQuin used?

    TetaQuin is prescribed to patients to prevent tetanus.

    Treatment depends on the patient's protection against tetanus, his/her vaccination status. If a patient is insufficiently protected against tetanus, treatment with TetaQuin may be proposed.

    Read more in the TetaQuin leaflet (pdf).

  • How is TetaQuin used?

    TetaQuin is a solution for an injection.

    To prevent tetanus, an intramuscular injection of TetaQuin can be administered.

    Read more in the TetaQuin leaflet (pdf).

  • What dosage of TetaQuin is administered?

    Children and adults receive the same dosage: 1 vial of TetaQuin (250 IU). The person treating the patient can decide to double the dosage if the wound was infected more than 24 hours before the treatment, or if an adult patient has a relatively high body weight. 

    Read more in the TetaQuin leaflet (pdf).

  • Administering TetaQuin

    To prevent tetanus TetaQuin can be injected into the patient’s upper arm or buttock.

    • Remove the vial from the refrigerator and allow it to reach room temperature.
    • It is a clear solution.
    • During the period of storage, slight turbidity or a small amount of precipitation may occur. This will not affect the efficacy of the product.
    • Dependent on the dosage, more than one vial may be used.
    • The content of several vials can be mixed for administration to the patient.
    • The product should be suctioned into a sterile syringe.

    Read more in the TetaQuin leaflet (pdf).

  • What are the side effects of TetaQuin?

    TetaQuin can cause side effects, in the same way as all other medicines. The patient may feel some pain or sensitivity at the site of the injection.

    The patient could develop a fever and/or a skin rash. Side effects such as nausea, vomiting, low blood pressure, a rapid heartbeat and hypersensitivity reactions are rare. 

    Read more in the TetaQuin leaflet (pdf).

  • How is TetaQuin stored?

    Store TetaQuin
    out of reach and sight of children
    in the refrigerator at 2 - 8 °C (therefore, do not freeze)
    in the original packaging to protect it from the light

    Not to be used after the expiry date
    Do not use TetaQuin after its expiry date. This is stipulated on the label, on the vial and on the box.

    Patients can hand any used medicines over to a pharmacy. By not disposing of medicines via waste water or household waste, we are helping to protect the environment.

    Read more in the TetaQuin leaflet (pdf).